Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Accured Expenses (2019 - 2025)

Allogene Therapeutics' Change in Accured Expenses history spans 7 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 57.04% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $478000.0, up 112.4%, while the annual FY2024 figure was -$1.3 million, 81.5% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $1.1 million at Allogene Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.9 million in Q3 2021 and bottomed at -$12.7 million in Q3 2023.
  • The 5-year median for Change in Accured Expenses is $1.1 million (2025), against an average of -$267684.2.
  • The largest YoY upside for Change in Accured Expenses was 906.99% in 2024 against a maximum downside of 1140.51% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$2.8 million in 2021, then soared by 213.33% to $3.1 million in 2022, then tumbled by 90.88% to $286000.0 in 2023, then soared by 906.99% to $2.9 million in 2024, then crashed by 62.29% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Change in Accured Expenses are $1.1 million (Q3 2025), $1.7 million (Q2 2025), and -$5.2 million (Q1 2025).